Tasly Pharmaceuticals, Inc. (TaslyUS), was founded in 2006 and is based in Rockville, Maryland. Tasly US is the overseas headquarters of Tasly Pharmaceuticals Group, Co. Ltd (Tasly), a China-based corporation trading publicly on the Shanghai exchange (SHA:600535). Tasly is an A-Share listed company with a current market capitalization of US $6 billion.
At Tasly our vision is to change the way the world takes and understands medicine. Through decades of research and development, we are geared to become a world-renowned innovator in pharmaceuticals, biologics, and nutraceuticals.
Our efforts have also been recognized as T89 (Dantonic) has become the first herbal medicine derived compound to complete an FDA Phase III global clinical trial with promising data. The results indicated that T89’s pharmacological functionalities in improving blood circulation, boosting energy metabolism level, and reducing blood thickness made the drug to express clinically significant benefits.
We look forward to this success paving the way for the future use of herbal medication as an effective and safe alternative to synthesized chemical and biological treatments.